Resources from the same session
3222 - Nab-paclitaxel (Nab) plus Gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): the GAP trial, a GISCAD phase II comparative randomized trial.
Presenter: Stefano Cascinu
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
5184 - Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): safety and biomarker data from the ICONIC trial safety run-in
Presenter: Michael Davidson
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4511 - POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Presenter: Pascal Hammel
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4623 - Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240
Presenter: Philippe Merle
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3561 - Comprehensive Genomic Profiling (CGP) of mixed hepatocellular cholangiocarcinomas (cHCC-CCA)
Presenter: Karthikeyan Murugesan
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4537 - Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
Presenter: Lorenza Rimassa
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3521 - Large-scale analysis of CDH1 mutations define a distinctive molecular subset in gastric cancer (GC)
Presenter: Jingyuan Wang
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
1484 - Genomic alterations predict clinical response to systemic chemotherapy and immune checkpoint blockade in biliary tract cancer
Presenter: Min Hwan Kim
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
1438 - Low-dose aspirin and risk of gastric and oesophageal cancer: a population-based study
Presenter: Luis Garcia Rodriguez
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4638 - Health-Related Quality of Life (HRQoL) Impact of Pembrolizumab (P) Versus Chemotherapy (C) as First-Line (1L) Treatment in PD-L1–Positive Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Presenter: Eric Van Cutsem
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract